# Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

> **NCT04111510** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Triple Negative Breast Cancer

## Interventions

- **DRUG:** Tumor infiltrating lymphocytes (TIL) LN-145

## Key facts

- **NCT ID:** NCT04111510
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-23
- **Primary completion:** 2023-01-30
- **Final completion:** 2023-05-11
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04111510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04111510, "Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04111510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*